PreciseDx raises $10.75M in funding

LabPulse.com staff writers
Jan 11, 2022
2021 06 02 20 19 9323 Business Computer Investigation Magnifying Glass 400

Cancer risk stratification company PreciseDx announced that it has raised $10.75 million in series A funding. The funds will be used to support the ongoing development and commercialization of its (artificial intelligence) AI-powered risk stratification platform.

Also, the company announced the appointment of Wayne Brinster to CEO, which was effective September 2021. Brinster has more than 30 years of experience and held management positions at MedTest, Wheaton Industries/DWK, Synthon Pharmaceuticals, and Becton Dickinson.

Latest in Cancer
Prostate Cancer 3 D Rendering Social
Veracyte to share bundle of genomic classifier studies at AUA 2024
April 16, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Bladder Urinary 3 D Social
Urine test halves use of invasive procedure to monitor bladder cancer
April 11, 2024
Lung Cancer Hotspot Social
U.K. researchers get funding for lung cancer vaccine development
April 4, 2024
Related Stories
Breast Cancer 3 D Social
Regulatory Approval
New York State Department of Health approves PreciseDx breast cancer LDT
Pathology Digital Workstation Microscope Social
Artificial Intelligence
PreciseDx, Dordrecht Albert Schweitzer Hospital to evaluate cancer risk stratification platform
2022 04 20 18 31 8041 Parkinsons Torn Newspaper 400
Home
PreciseDx touts AI software for early detection of Parkinson's
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Cancer
Veracyte to share bundle of genomic classifier studies at AUA 2024
By LabPulse.com staff writers
Veracyte has announced that the American Urological Association's May meeting will feature nine sessions related to evaluations of its prostate cancer and bladder cancer genomic tests.
April 16, 2024
Prostate Cancer 3 D Rendering Social
Lipid enzyme blocker renders prostate cancer cells vulnerable to PARP inhibitors in study
By Nick Paul Taylor
Blocking lipid synthesis enhanced the effect of PARP inhibitors on prostate cancer in a preclinical study, pointing to a potential way to make the treatments effective in more patients.
April 15, 2024
Cancer Cells Prostate Social
Urine test halves use of invasive procedure to monitor bladder cancer
By Nick Paul Taylor
A urine test can cut the number of cystoscopies necessary to follow up high-risk bladder cancer patients without increasing the risk of recurrence, a study has found.
April 11, 2024
Bladder Urinary 3 D Social
U.K. researchers get funding for lung cancer vaccine development
By Matt Limb
Researchers are working to develop a lung cancer vaccine in the U.K. with 1.7 million pounds ($2.2 million) funding from leading charities.
April 4, 2024
Lung Cancer Hotspot Social
Castle Biosciences shares melanoma test study data at SSO 2024
By LabPulse.com staff writers
Castle Biosciences shared data from two studies on the performance of its DecisionDx-Melanoma test in patients with cutaneous melanoma at the Society of Surgical Oncology 2024 (SSO 2024) annual meeting, held March 20-23 in Atlanta.
March 26, 2024
Melanoma Social
Ibex presents new study data for AI-powered cancer diagnostics platform
By Matt Limb
Ibex Medical Analytics is hailing positive data from studies with U.S. partners on the impact of its artificial intelligence (AI)-powered cancer diagnostic platform Galen.
March 26, 2024
Artificial Intelligence Ai Hand Social
Study sheds light on the organization of immune cells in tumors
By Matt Limb
Researchers have revealed how immune cells are spatially organized within some tumors and that certain immune “hubs” may be linked to better cancer treatment responses.
March 27, 2024
Cancer Cell Target2 Social
Bio-Techne receives IVDR certification for chronic myeloid leukemia monitoring test
By LabPulse.com staff writers
Bio-Techne has announced that Asuragen, part of its molecular diagnostics division, has completed class C certification under the new European Union IVDR for its QuantideX qPCR BCR-ABL IS kit for monitoring chronic myeloid leukemia.
March 22, 2024
Blood Test Samples Lab Social
MIT team develops genome-editing approach for cancer mutation screening
By Matt Limb
Scientists say they have developed a method to screen cancer-associated genetic mutations more easily and quickly than any existing approach.
March 22, 2024
Dna Cancer Cell Social
ChromaCode partners with the Medical College of Georgia on NSCLC assay validation
By LabPulse.com staff writers
ChromaCode announced a partnership with the Medical College of Georgia to test the analytical and clinical performance of ChromaCode's HDPCR non-small cell lung cancer (NSCLC) biomarker assay.
March 21, 2024
Cancer Lung Social
Machine-learning model predicts lung and liver cancer through genome sequence changes
By LabPulse.com staff writers
Researchers have developed a machine-learning approach that may potentially predict early-stage lung or liver cancer by detecting repetitive sequences in the genome.
March 15, 2024
Artificial Intelligence Lung Color Social
Study: AI assists discovery of prostate cancer subtypes
By Matt Limb
Prostate tumors have been found to evolve along multiple pathways, leading to two distinct disease types with “pivotal” implications for diagnosis and treatment, say scientists.
March 8, 2024
3 D Prostate Cancer Viral Social
Page 1 of 95
Next Page